Skip to main content

Table 1 Patient and treatment characteristics

From: Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer

 

Number

Percent

Patient characteristics

 Age at treatment (yrs), median (range)

69.2

(46.4–86.8)

 Sex

  Female

3

14.3

  Male

18

85.7

 ECOG PS

  0–1

12

57.1

  2

9

42.9

 Pathology

  Squamous cell carcinoma

21

100.0

  Adenocarcinoma

0

0.0

 Site

  Upper thoracic (UI 20–25 cm)

5

23.8

  Middle thoracic (UI 25–30 cm)

9

42.9

  Lower thoracic (UI 30–40 cm)

7

33.3

 Stage

  I

1

4.8

  IIB

4

19.0

  IIIA

3

14.3

  IIIB

7

33.3

  IIIC

6

28.6

Treatment characteristics

 Aim

  Definitive

17

81.0

  Preop

4

19.0

 Concurrent chemotherapy

19

90.5

 Chemotherapy regimen (n = 19)

  5-Fluorouracil+cisplatin

18

94.7

  5-Fluorouracil monotherapy

1

5.3

 RT modality

  IMRT

21

100.0

  3D-CRT

0

0.0

 Median total dose (Gy), median (range)

63

(44.1–69.3)

 Median fraction dose (Gy), median (range)

2.1

(1.8–2.1)

 Fractions of RT completed before mid-radiotherapy PET (fractions), median (range)

11

(9–12)

 Dose of RT completed before mid-radiotherapy PET (Gy), median (range)

23.1

(18.9–25.2)

  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UI upper incisor, RT radiotherapy, IMRT intensity-modulated radiotherapy, 3D-CRT 3 dimensional-conformal radiotherapy